Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma
03 medical and health sciences
0302 clinical medicine
dnam-1; tumor immunology; multiple myeloma; nkg2d; nk cells
Author's View
3. Good health
DOI:
10.4161/onci.26663
Publication Date:
2014-01-21T19:34:48Z
AUTHORS (6)
ABSTRACT
Malignant cells constitutively express Natural killer group 2, member D (NKG2D) or DNAX Accessory Molecule-1 (DNAM-1) ligands, yet they are often unable to trigger a robust cytotoxic cell response. It may be therapeutically useful to implement strategies aimed at increasing the density of NKG2D and DNAM-1 ligands on the surface of cancer cells, endowing them with the capacity to activate potent antitumor natural killer-cell responses.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (10)
CITATIONS (35)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....